Hyperfibrinogenemia predicts long-term risk of death after ischemic stroke

go back to reference Koenig W (2003) Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 89:601–609PubMed Koenig W (2003) Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 89:601–609PubMed

go back to reference Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, Caslake M, Butterworth AS, Amouyel P, Assmann G, Bakker SJ, Barr EL, Barrett-Connor E, Benjamin EJ, Björkelund C, Brenner H, Brunner E, Clarke R, Cooper JA, Cremer P, Cushman M, Dagenais GR, D’Agostino RB Sr, Dankner R, Davey-Smith G, Deeg D, Dekker JM, Engström G, Folsom AR, Fowkes FG, Gallacher J, Gaziano JM, Giampaoli S, Gillum RF, Hofman A, Howard BV, Ingelsson E, Iso H, Jørgensen T, Kiechl S, Kitamura A, Kiyohara Y, Koenig W, Kromhout D, Kuller LH, Lawlor DA, Meade TW, Nissinen A, Nordestgaard BG, Onat A, Panagiotakos DB, Psaty BM, Rodriguez B, Rosengren A, Salomaa V, Kauhanen J, Salonen JT, Shaffer JA, Shea S, Ford I, Stehouwer CD, Strandberg TE, Tipping RW, Tosetto A, Wassertheil-Smoller S, Wennberg P, Westendorp RG, Whincup PH, Wilhelmsen L, Woodward M, Lowe GD, Wareham NJ, Khaw KT, Sattar N, Packard CJ, Gudnason V, Ridker PM, Pepys MB, Thompson SG, Danesh J (2012) C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 367:1310–1320PubMedCrossRef Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, Caslake M, Butterworth AS, Amouyel P, Assmann G, Bakker SJ, Barr EL, Barrett-Connor E, Benjamin EJ, Björkelund C, Brenner H, Brunner E, Clarke R, Cooper JA, Cremer P, Cushman M, Dagenais GR, D’Agostino RB Sr, Dankner R, Davey-Smith G, Deeg D, Dekker JM, Engström G, Folsom AR, Fowkes FG, Gallacher J, Gaziano JM, Giampaoli S, Gillum RF, Hofman A, Howard BV, Ingelsson E, Iso H, Jørgensen T, Kiechl S, Kitamura A, Kiyohara Y, Koenig W, Kromhout D, Kuller LH, Lawlor DA, Meade TW, Nissinen A, Nordestgaard BG, Onat A, Panagiotakos DB, Psaty BM, Rodriguez B, Rosengren A, Salomaa V, Kauhanen J, Salonen JT, Shaffer JA, Shea S, Ford I, Stehouwer CD, Strandberg TE, Tipping RW, Tosetto A, Wassertheil-Smoller S, Wennberg P, Westendorp RG, Whincup PH, Wilhelmsen L, Woodward M, Lowe GD, Wareham NJ, Khaw KT, Sattar N, Packard CJ, Gudnason V, Ridker PM, Pepys MB, Thompson SG, Danesh J (2012) C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 367:1310–1320PubMedCrossRef

go back to reference Turaj W, Słowik A, Dziedzic T, Pułyk R, Adamski M, Strojny J, Szczudlik A (2006) Increased plasma fibrinogen predicts one-year mortality in patients with acute ischemic stroke. J Neurol Sci 246:13–19PubMedCrossRef Turaj W, Słowik A, Dziedzic T, Pułyk R, Adamski M, Strojny J, Szczudlik A (2006) Increased plasma fibrinogen predicts one-year mortality in patients with acute ischemic stroke. J Neurol Sci 246:13–19PubMedCrossRef

go back to reference González-Conejero R, Fernández-Cadenas I, Iniesta JA, Marti-Fabregas J, Obach V, Alvarez-Sabín J, Vicente V, Corral J, Montaner J, Proyecto Ictus Research Group (2006) Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients. Stroke 37:2288–2293PubMedCrossRef González-Conejero R, Fernández-Cadenas I, Iniesta JA, Marti-Fabregas J, Obach V, Alvarez-Sabín J, Vicente V, Corral J, Montaner J, Proyecto Ictus Research Group (2006) Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients. Stroke 37:2288–2293PubMedCrossRef

go back to reference Tanne D, Macko RF, Lin Y, Tilley BC, Levine SR, NINDS rtPA Stroke Study Group (2006) Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke. Stroke 37:1798–1804PubMedCrossRef Tanne D, Macko RF, Lin Y, Tilley BC, Levine SR, NINDS rtPA Stroke Study Group (2006) Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke. Stroke 37:1798–1804PubMedCrossRef

go back to reference del Zoppo GJ, Levy DE, Wasiewski WW, Pancioli AM, Demchuk AM, Trammel J, Demaerschalk BM, Kaste M, Albers GW, Ringelstein EB (2009) Hyperfibrinogenemia and functional outcome from acute ischemic stroke. Stroke 40:1687–1691PubMedCrossRefPubMedCentral del Zoppo GJ, Levy DE, Wasiewski WW, Pancioli AM, Demchuk AM, Trammel J, Demaerschalk BM, Kaste M, Albers GW, Ringelstein EB (2009) Hyperfibrinogenemia and functional outcome from acute ischemic stroke. Stroke 40:1687–1691PubMedCrossRefPubMedCentral

go back to reference Whiteley W, Jackson C, Lewis S, Lowe G, Rumley A, Sandercock P, Wardlaw J, Dennis M, Sudlow C (2009) Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6. PLoS Med 6:e1000145PubMedCrossRefPubMedCentral Whiteley W, Jackson C, Lewis S, Lowe G, Rumley A, Sandercock P, Wardlaw J, Dennis M, Sudlow C (2009) Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6. PLoS Med 6:e1000145PubMedCrossRefPubMedCentral

go back to reference van den Herik EG, Cheung EY, de Lau LM, den Hertog HM, Leebeek FW, Dippel DW, Koudstaal PJ, de Maat MP (2011) γ’/total fibrinogen ratio is associated with short-term outcome in ischaemic stroke. Thromb Haemost 105:430–434PubMedCrossRef van den Herik EG, Cheung EY, de Lau LM, den Hertog HM, Leebeek FW, Dippel DW, Koudstaal PJ, de Maat MP (2011) γ’/total fibrinogen ratio is associated with short-term outcome in ischaemic stroke. Thromb Haemost 105:430–434PubMedCrossRef

go back to reference Rallidis LS, Vikelis M, Panagiotakos DB, Liakos GK, Krania E, Kremastinos DT (2008) Usefulness of inflammatory and haemostatic markers to predict short-term risk for death in middle-aged ischaemic stroke patients. Acta Neurol Scand 117:415–420PubMedCrossRef Rallidis LS, Vikelis M, Panagiotakos DB, Liakos GK, Krania E, Kremastinos DT (2008) Usefulness of inflammatory and haemostatic markers to predict short-term risk for death in middle-aged ischaemic stroke patients. Acta Neurol Scand 117:415–420PubMedCrossRef

go back to reference Resch KL, Ernst E, Matrai A, Paulsen HF (1992) Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors. Ann Intern Med. 117:371–375PubMedCrossRef Resch KL, Ernst E, Matrai A, Paulsen HF (1992) Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors. Ann Intern Med. 117:371–375PubMedCrossRef

go back to reference Woodward M, Lowe GD, Campbell DJ, Colman S, Rumley A, Chalmers J, Neal BC, Patel A, Jenkins AJ, Kemp BE, MacMahon SW (2005) Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke 36:2143–2147PubMedCrossRef Woodward M, Lowe GD, Campbell DJ, Colman S, Rumley A, Chalmers J, Neal BC, Patel A, Jenkins AJ, Kemp BE, MacMahon SW (2005) Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke 36:2143–2147PubMedCrossRef

go back to reference Di Napoli M, Papa F, Villa Pini Stroke Data Bank Investigators (2002) Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk ofnew cardiovascular events in first-ever ischemic stroke patients. Stroke 33:1763–1771PubMedCrossRef Di Napoli M, Papa F, Villa Pini Stroke Data Bank Investigators (2002) Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk ofnew cardiovascular events in first-ever ischemic stroke patients. Stroke 33:1763–1771PubMedCrossRef

go back to reference Beamer NB, Coull BM, Clark WM, Briley DP, Wynn M, Sexton G (1998) Persistent inflammatory response in stroke survivors. Neurology 50:1722–1728PubMedCrossRef Beamer NB, Coull BM, Clark WM, Briley DP, Wynn M, Sexton G (1998) Persistent inflammatory response in stroke survivors. Neurology 50:1722–1728PubMedCrossRef

go back to reference Shenhar-Tsarfaty S, Ben Assayag E, Bova I, Shopin L, Cohen M, Berliner S, Shapira I, Bornstein NM (2008) Persistent hyperfibrinogenemia in acute ischemic stroke / transient ischemic attack (TIA). Thromb Haemost 99:169–173PubMed Shenhar-Tsarfaty S, Ben Assayag E, Bova I, Shopin L, Cohen M, Berliner S, Shapira I, Bornstein NM (2008) Persistent hyperfibrinogenemia in acute ischemic stroke / transient ischemic attack (TIA). Thromb Haemost 99:169–173PubMed

go back to reference Tousoulis D, Papageorgiou N, Androulakis E, Briasoulis A, Antoniades C, Stefanadis C (2011) Fibrinogen and cardiovascular disease: genetics and biomarkers. Blood Rev 25:239–245PubMedCrossRef Tousoulis D, Papageorgiou N, Androulakis E, Briasoulis A, Antoniades C, Stefanadis C (2011) Fibrinogen and cardiovascular disease: genetics and biomarkers. Blood Rev 25:239–245PubMedCrossRef

go back to reference de Maat MP, Verschuur M (2005) Fibrinogen heterogeneity: inherited and noninherited. Curr Opin Hematol 12:377–383PubMedCrossRef de Maat MP, Verschuur M (2005) Fibrinogen heterogeneity: inherited and noninherited. Curr Opin Hematol 12:377–383PubMedCrossRef

go back to reference Rothwell PM, Howard SC, Power DA, Gutnikov SA, Algra A, van Gijn J, Clark TG, Murphy MF, Warlow CP (2004) Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke. Stroke 35:2300–2305PubMedCrossRef Rothwell PM, Howard SC, Power DA, Gutnikov SA, Algra A, van Gijn J, Clark TG, Murphy MF, Warlow CP (2004) Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke. Stroke 35:2300–2305PubMedCrossRef

go back to reference Fibrinogen Studies Collaboration (2005) Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294:1799–1809 Fibrinogen Studies Collaboration (2005) Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294:1799–1809

go back to reference Ahmadi-Abhari S, Luben RN, Wareham NJ, Khaw KT (2013) Seventeen year risk of all-cause and cause-specific mortality associated with C-reactive protein, fibrinogen and leukocyte count in men and women: the EPIC-Norfolk study. Eur J Epidemiol 28:541–550PubMedCrossRef Ahmadi-Abhari S, Luben RN, Wareham NJ, Khaw KT (2013) Seventeen year risk of all-cause and cause-specific mortality associated with C-reactive protein, fibrinogen and leukocyte count in men and women: the EPIC-Norfolk study. Eur J Epidemiol 28:541–550PubMedCrossRef

go back to reference Toss H, Lindahl B, Siegbahn A, Wallentin L (1997) Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 96:4204–4210PubMedCrossRef Toss H, Lindahl B, Siegbahn A, Wallentin L (1997) Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 96:4204–4210PubMedCrossRef

go back to reference Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Pagano G, Cavallo-Perin P, Casale Monferrato Study (2005) Fibrinogen and AER are major independent predictors of 11-year cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetologia 48:427–434PubMedCrossRef Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Pagano G, Cavallo-Perin P, Casale Monferrato Study (2005) Fibrinogen and AER are major independent predictors of 11-year cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetologia 48:427–434PubMedCrossRef

go back to reference Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Stancanelli B, Nicocia G, Buemi M (2003) Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure. J Intern Med 254:132–139PubMedCrossRef Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Stancanelli B, Nicocia G, Buemi M (2003) Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure. J Intern Med 254:132–139PubMedCrossRef

go back to reference Goicoechea M, de Vinuesa SG, Gómez-Campderá F, Aragoncillo I, Verdalles U, Mosse A, Luño J (2008) Serum fibrinogen levels are an independent predictor of mortality in patients with chronic kidney disease (CKD) stages 3 and 4. Kidney Int Suppl. 111:S67–S70PubMedCrossRef Goicoechea M, de Vinuesa SG, Gómez-Campderá F, Aragoncillo I, Verdalles U, Mosse A, Luño J (2008) Serum fibrinogen levels are an independent predictor of mortality in patients with chronic kidney disease (CKD) stages 3 and 4. Kidney Int Suppl. 111:S67–S70PubMedCrossRef